StrideBio.

* Gene-editing technology startup StrideBio struck a deal with Massachusetts-based Sarepta Therapeutics that could be worth $90 million plus royalties in exchange for the rights to eight potential gene-based therapies. StrideBio will...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT